Genetic Constrained Graph Variational Autoencoder for COVID-19 Drug Discovery

• URL: http://arxiv.org/abs/2104.11674v1
• Date: Fri, 23 Apr 2021 16:10:15 GMT
• Title: Genetic Constrained Graph Variational Autoencoder for COVID-19 Drug Discovery
• Authors: Tianyue Cheng, Tianchi Fan, Landi Wang
• Abstract summary: We propose a new model called Genetic Constrained Graph Variational Autoencoder (GCGVAE) to solve this problem. We trained our model based on the data of various viruses' protein structure, including that of the SARS, HIV, Hep3, and MERS, and used it to generate possible drugs for SARS-CoV-2. Our generated molecules have great effectiveness in inhibiting SARS-CoV-2.
• Score: 0.0
• License: http://creativecommons.org/licenses/by-nc-nd/4.0/
• Abstract: In the past several months, COVID-19 has spread over the globe and caused severe damage to the people and the society. In the context of this severe situation, an effective drug discovery method to generate potential drugs is extremely meaningful. In this paper, we provide a methodology of discovering potential drugs for the treatment of Severe Acute Respiratory Syndrome Corona-Virus 2 (commonly known as SARS-CoV-2). We proposed a new model called Genetic Constrained Graph Variational Autoencoder (GCGVAE) to solve this problem. We trained our model based on the data of various viruses' protein structure, including that of the SARS, HIV, Hep3, and MERS, and used it to generate possible drugs for SARS-CoV-2. Several optimization algorithms, including valency masking and genetic algorithm, are deployed to fine tune our model. According to the simulation, our generated molecules have great effectiveness in inhibiting SARS-CoV-2. We quantitatively calculated the scores of our generated molecules and compared it with the scores of existing drugs, and the result shows our generated molecules scores much better than those existing drugs. Moreover, our model can be also applied to generate effective drugs for treating other viruses given their protein structure, which could be used to generate drugs for future viruses.

Related papers

• Regressor-free Molecule Generation to Support Drug Response Prediction [83.25894107956735]
  Conditional generation based on the target IC50 score can obtain a more effective sampling space. Regressor-free guidance combines a diffusion model's score estimation with a regression controller model's gradient based on number labels.
  arXiv  Detail & Related papers  (2024-05-23T13:22:17Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Neural Bandits for Data Mining: Searching for Dangerous Polypharmacy [63.135687276599114]
  Some polypharmacies, deemed inappropriate, may be associated with adverse health outcomes such as death or hospitalization. We propose the OptimNeuralTS strategy to efficiently mine claims datasets and build a predictive model of the association between drug combinations and health outcomes. Our method can detect up to 72% of PIPs while maintaining an average precision score of 99% using 30 000 time steps.
  arXiv  Detail & Related papers  (2022-12-10T03:43:23Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• Benchmarking Machine Learning Robustness in Covid-19 Genome Sequence Classification [109.81283748940696]
  We introduce several ways to perturb SARS-CoV-2 genome sequences to mimic the error profiles of common sequencing platforms such as Illumina and PacBio. We show that some simulation-based approaches are more robust (and accurate) than others for specific embedding methods to certain adversarial attacks to the input sequences.
  arXiv  Detail & Related papers  (2022-07-18T19:16:56Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• Deep Graph Convolutional Network and LSTM based approach for predicting drug-target binding affinity [0.0]
  We propose a novel architecture that predicts binding affinity values between the FDA-approved drugs and the viral proteins of SARS-CoV-2. On the basis of the Combined Score, we prepare a list of the top-18 drugs with the highest binding affinity for 5 viral proteins present in SARS-CoV-2.
  arXiv  Detail & Related papers  (2022-01-18T10:57:05Z)
• Heterogeneous network-based drug repurposing for COVID-19 [7.097880564431694]
  The Corona Virus Disease 2019 (COVID-19) belongs to human coronaviruses (HCoVs), which spreads rapidly around the world. Compared with new drug development, drug repurposing may be the best shortcut for treating COVID-19. We constructed a comprehensive heterogeneous network based on the HCoVs-related target proteins and use the previously proposed deepDTnet to discover potential drug candidates for COVID-19.
  arXiv  Detail & Related papers  (2021-07-20T01:24:40Z)
• Evening the Score: Targeting SARS-CoV-2 Protease Inhibition in Graph Generative Models for Therapeutic Candidates [11.853524110656991]
  We look at the therapeutic design of novel drug candidates targeting SARS-CoV-2 viral proteins. We use an autoencoder that generates molecules with similar structures to a dataset of drugs with anti-SARS activity. During generation, we explore optimization toward several design targets to balance druglikeness, synthetic accessability, and anti-SARS activity.
  arXiv  Detail & Related papers  (2021-05-07T18:39:25Z)
• Dr-COVID: Graph Neural Networks for SARS-CoV-2 Drug Repurposing [14.112444998191698]
  We propose a dedicated graph neural network (GNN) based drug repurposing model, called Dr-COVID. Dr-COVID is evaluated in terms of its prediction performance and its ability to rank the known treatment drugs for diseases as high as possible.
  arXiv  Detail & Related papers  (2020-12-03T18:34:10Z)
• Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence [9.472330151855111]
  We built a SARS-CoV-2 knowledge graph based on the interactions among virus baits, host genes, pathways, drugs, and phenotypes. We prioritized the candidate drugs using clinical trial history, and then validated them with their genetic profiles, in vitro experimental efficacy, and electronic health records.
  arXiv  Detail & Related papers  (2020-09-23T04:47:59Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.